Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Iberdomide Shows Promise in Heavily Pretreated Multiple Myeloma

September 15th 2019

The novel agent iberdomide (formerly CC-220) was safe and showed antitumor activity when combined with dexamethasone in patients with heavily pretreated, relapsed/refractory multiple myeloma, according to findings from a phase Ib/IIa study presented at the 17th International Myeloma Workshop.

Isatuximab Triplet Showcases Encouraging PFS in High-Risk Multiple Myeloma

September 15th 2019

Adding the CD38-directed monoclonal antibody isatuximab in combination with pomalidomide and dexamethasone improved progression-free survival in both standard-risk patients with relapsed/refractory multiple myeloma and those with high-risk cytogenetics.

Isatuximab Quadruplet Active in High-Risk, Newly Diagnosed Myeloma

September 14th 2019

A quadruplet regimen combining the anti-CD38 monoclonal antibody isatuximab with carfilzomib, lenalidomide, and dexamethasone was safe and had a 100% response rate among 10 patients enrolled in the safety run-in cohort of the phase II, multicenter GMMG-CONCEPT trial.

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma

September 14th 2019

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

Dr. Weisel on INSIGHT MM Analysis of Duration of Therapy in Myeloma

September 14th 2019

Katja Weisel, MD, myeloma specialist at the University of Tübingen, discusses an analysis of the INSIGHT MM study evaluating fixed-duration versus continuous therapy for patients with multiple myeloma.

Daratumumab-VTd Regimen Shows Benefit in Newly Diagnosed High-Risk Multiple Myeloma

September 14th 2019

Pieter Sonneveld, MD, PhD, discusses the significance of the subgroup analysis of the phase III CASSIOPEIA trial evaluating the regimen of daratumumab, bortezomib, thalidomide, and dexamethasone in patients with high-risk multiple myeloma.

Dr. Voorhees on the ELOQUENT-3 Trial in Late Relapsed/Refractory Multiple Myeloma

September 12th 2019

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma

September 11th 2019

Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.

Dr. Larson on Potentially Practice-Changing Data in Frontline Multiple Myeloma

September 6th 2019

Sarah M. Larson, MD, discusses potentially practice-changing studies for patients with transplant-eligible and -ineligible multiple myeloma.

Encouraging Data Advance Research in Relapsed/Refractory Myeloma

September 5th 2019

Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.

Mapping Multiple Myeloma Advances in NYC

September 4th 2019

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

Novel Frontline Approaches Induce Deep, Durable Responses in Multiple Myeloma

September 3rd 2019

Michael A. Rosenzweig, MD, MS, discusses changes in the frontline setting of multiple myeloma.

Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

August 30th 2019

Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

Genomic Testing Puts Myeloma Paradigm on Personalized Path

August 30th 2019

Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.

Novel Antibody-Based Approaches on Horizon in Multiple Myeloma

August 30th 2019

Hearn Jay Cho, MD, PhD, provides background on these novel approaches, while highlighting exciting trials to look for in the future.

Jagannath Shares Insight on Treatment Strategies in Relapsed/Refractory Myeloma

August 28th 2019

Sundar Jagannath, MD, highlights the current state of the relapsed/refractory multiple myeloma paradigm and research regarding next steps for advancing treatment.

Elotuzumab Triplet Approved in Europe for Multiple Myeloma

August 28th 2019

The European Commission has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Dr. Cowan on the Future of Selinexor in Multiple Myeloma

August 23rd 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine, and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the future of selinexor (Xpovio) in multiple myeloma.

Daratumumab/VMP Combo Approved in Japan for Frontline Myeloma

August 22nd 2019

The Japanese Ministry of Health, Labor and Welfare has approved daratumumab for use in combination with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Published Selinexor Data Show Sustained Survival in Heavily Pretreated Myeloma

August 22nd 2019

Selinexor in combination with twice-weekly dexamethasone led to a median overall survival of 15.6 months in patients with heavily pretreated multiple myeloma who had a minimal response or better to the novel agent compared with 1.7 months in those whose disease progressed or had unevaluable responses.